Despite ongoing controversy, homeopathy has become increasingly accepted as a "medical reality" by patients and doctors alike. This process has been accompanied by an increased quality of manufacturing, education, research, and regulation of homeopathy. This paper argues that European regulation may now have gone too far by indiscriminately prescribing that homeopathic medicines should be used in a potency of D4 and higher. Low potencies and tinctures are an important and integral part of the homeopathic heritage. The regulatory environment therefore appears to be hampering one of its own principal aims: the availability of safe and high-quality homeopathic products that practitioners, patients and consumers want and need.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10354-005-0231-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGE-EP4 Axis in BMP-2-Induced Mouse Mesenchymal Stem Cells.
Molecules
December 2024
Graduate School of Pharmaceutical Sciences, Hiroshima International University, 5-1-1, Hirokoshingai, Kure 737-0112, Japan.
Farnesoid X receptor (FXR), a nuclear receptor, is expressed in calvaria and bone marrow stromal cells and plays a role in bone homeostasis. However, the mechanism of FXR-activated osteoblast differentiation remains unclear. In this study, we investigated the regulatory mechanism underlying FXR-activated osteoblast differentiation using bone morphogenetic protein-2 (BMP-2)-induced mouse ST-2 mesenchymal stem cells.
View Article and Find Full Text PDFSiblings With Berardinelli-Seip Congenital Lipodystrophy: Clinical Insights and Challenges.
Cureus
December 2024
Pharmacy, Punjab University College of Pharmacy, Lahore, PAK.
Berardinelli-Seip congenital lipodystrophy (BSCL), also known as congenital generalized lipodystrophy (CGL), is an exceptionally rare autosomal recessive disorder marked by a significant deficiency of adipose tissue throughout the body. This lack of adipose tissue, normally found beneath the skin and between internal organs, leads to impaired adipocyte formation and fat storage, causing lipids to accumulate in atypical tissues such as muscles and the liver. The extent of adipose tissue loss directly influences the severity of symptoms, which can include a muscular appearance, increased appetite, bone cysts, marrow fat depletion, acromegalic features, severe insulin resistance, skeletal muscle hypertrophy, hypertrophic cardiomyopathy, hepatic steatosis, hepatomegaly, cirrhosis, and intellectual disability.
View Article and Find Full Text PDFReducing Greenhouse Gas Emissions and Modifying Nitrous Oxide Delivery at Stanford: Observational, Pilot Intervention Study.
JMIR Perioper Med
January 2025
Stanford Hospital, Stanford, CA, United States.
Background: Inhalational anesthetic agents are a major source of potent greenhouse gases in the medical sector, and reducing their emissions is a readily addressable goal. Nitrous oxide (NO) has a long environmental half-life relative to carbon dioxide combined with a low clinical potency, leading to relatively large amounts of NO being stored in cryogenic tanks and H cylinders for use, increasing the chance of pollution through leaks. Building on previous findings, Stanford Health Care's (SHC's) NO emissions were analyzed at 2 campuses and targeted for waste reduction as a precursor to system-wide reductions.
View Article and Find Full Text PDFColon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid.
Pharmaceutics
December 2024
College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
In addition to oncological applications, poly(ADP-ribose) polymerase (PARP) inhibitors have potential as anti-inflammatory agents. Colon-targeted delivery of PARP inhibitors has been evaluated as a pharmaceutical strategy to enhance their safety and therapeutic efficacy against gut inflammation. Colon-targeted PARP inhibitors 5-aminoisoquinoline (5-AIQ) and 3-aminobenzamide (3-AB) were designed and synthesized by azo coupling with salicylic acid (SA), yielding 5-AIQ azo-linked with SA (AQSA) and 3-AB azo-linked with SA (ABSA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!